LiquidBiopsy® Testing Services
The Highly Sensitive Blood Test to Analyze and Molecularly Characterize Tumor DNA
Cynvenio’s LiquidBiopsy® assay for solid tumors provides efficient and reliable tumor DNA recovery from whole blood samples. Once recovered, ctcDNA can be returned to the client for in-house analysis or processed at the LiquidBiopsy CLIA lab for analysis of mutational hot spots across 50 oncogenes.
The LiquidBiopsy® test uniquely supports NGS based analysis of both ctDNA and ctcDNA. As such it is the only approach that acknowledges shared and emerging utility of ctcDNA and ctDNA.
Supporting Research & Clinical Trial Management
LiquidBiopsy test results can offer early surrogate readout of treatment response, help identify clinically relevant patient sub-populations, and enable adaptive clinical trials, and ultimately, support the development of highly tumor-specific therapies.
Blood samples from subjects can be drawn and the tumor DNA immediately analyzed, or banked for later analysis.
- Ease of sample collection and the ability to bank samples enables multi-country clinical trials.
- Resistant or responsive clones within a tumor are accessible even if they occur at a frequency of 1% in the blood.
- Analysis supports ctcDNA as well as ctDNA.
- Rapid "sample-to-sequence" turn-around time.
Easy Sample Collection & Transport
LiquidBiopsy kits are designed to simplify the collection of tumor cell and cell-free templates for transport to the lab. The kit includes a custom stabilizer and easy-to-follow instructions for shipping the samples for up to 96 hours at ambient temperature. This 4-day window allows for a streamlined collection process and global transport of samples with no cold-chain requirements.